GROUNDING — the individualized (N-of-1) manufacturing process for intismeran
Source A — Moderna, “Individualized Neoantigen Therapies” (primary company description)
- URL: https://www.modernatx.com/media-center/all-media/blogs/individual.neoantigen-therapies
- Accessed: 2026-08-21
- Exact query: WebSearch
Moderna individualized neoantigen therapy manufacturing turnaround time weeks personalized cancer vaccine INT facility scale, then WebFetch of the Moderna page with a prompt asking verbatim for the end-to-end process: biopsy, sequencing, neoantigen algorithm, count, facility, turnaround, vialing/shipping, route.
Verbatim passages
“a study participant has their blood drawn and their tumor biopsied. Sequencing is then performed in a lab to compare data from the tumor biopsy sample and the study participant’s healthy blood cells”
A proprietary algorithm developed with Merck “reviews these mutations and predicts up to 34 of those mutations that are believed to help the study participant’s immune system better recognize tumor cells”
“sent to our manufacturing facility in Norwood, MA, where the individualized neoantigen therapy is manufactured.”
“The individualized neoantigen therapy is then placed in a vial and shipped back to the clinical trial site where a healthcare professional administers it to the study patient via intramuscular injection.”
- NOT STATED on this page: turnaround / “needle to needle” time.
Source B — press reporting on turnaround and facility (SECONDARY)
- Accessed: 2026-08-21
- Exact query: same WebSearch as above. Reported over Boston Globe / MedCity News / BioPharm International hits:
“The development and manufacturing of a personalized therapy has to happen within about six weeks from when a patient’s tumor is sampled. More specifically, in the trial it was done at a ‘needle to needle’ time of six weeks, referring to the time from initial tumor sampling to vaccine administration.”
“The vaccine, called intismeran, was made at Moderna’s Marlborough manufacturing facility … Moderna announced that they are building a manufacturing site in Marlborough, MA as a commercial INT manufacturing facility.”
- Evidential weight: SECONDARY, press-reported, and internally inconsistent with Source A on facility (Norwood vs Marlborough). Use the six-week figure only as press-reported, and do not assert a single facility.
Evidential weight — what “bespoke” actually means here
- STATES: the per-patient variable is the mRNA coding sequence — which up-to-34 neoantigens the algorithm selects from that patient’s tumour-vs-blood sequencing comparison. Everything downstream is a fixed process: same synthesis chemistry, same LNP, same 1 mg dose, same q3w x 9 schedule, same intramuscular route, same manufacturing line, same vial.
- Bridging derivation (mine, labelled INFERENCE): this is sequence-level individualization on an invariant platform. The regulatory and manufacturing precedent it sets is therefore “a fixed, validated platform whose payload sequence may vary per patient” — not “any per-patient therapeutic can be built and cleared”. A STRC therapy would need to change payload and route and target tissue and formulation relative to any validated platform, and would therefore not inherit the platform’s validated status.
- NOT STATED anywhere retrieved: that intismeran or its LNP holds an FDA platform technology designation; that the platform has ever been applied to a non-oncology or non-IM indication.